Faculty

Renato G. Martins MD,MPH

Renato G. Martins, MD, MPH

Professor,
Department of Medicine, Division of Oncology
University of Washington

Service Medical Director, Outpatient General Oncology/Hematology
Seattle Cancer Care Alliance

Clinical Research Program Director, Thoracic Oncology
Seattle Cancer Care Alliance

Associate Medical Director, Non-Transplant Adult Oncology
Seattle Cancer Care Alliance
Seattle, Washington

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave W, G4-940
Seattle, WA 98109-1023

Admin Contact

Céline Abell
206.288.6683
hnlprogram@seattlecca.org
Fax:  206.288.2226

Specialty / Expertise

Head, Neck, Lung, and Thyroid Cancer

Research Interests

Cancer of:

  • Head
  • Neck
  • Lung
  • Thyroid

Current Research Projects

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non small Cell Lung Carcinoma who have EGFR-positive Tumors (RADIANT).
Principal Investigator: Keith Eaton. Role: Co-Investigator.

Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastic Medullary Carcinoma of thyroid with Functional Imaging Correlation (THOR 6494).
Role: Principal Investigator

Registration Phase III Study of Lucanix (belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blind, Placebo-controlled Study of Lucanix Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy (NOVARX).
Principal Investigator: Keith Eaton. Role: Co-Investigator

Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (HOPE 201).
Role: Principal Investigator

A Phase 2, Open-label Trial of PF-00299804 in Untreated Advanced Adenocarcinoma of the Lung in Never or Former Light Smokers (PANHER A7471017).
Role: Principal Investigator

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer (BAYER 14295).
Role: Principal Investigator

Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF 02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (PFIZER A8081005).
Role: Principal Investigator

Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (S132).
Principal Investigator: Laura Chow. Role: Co-Investigator

A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination with OSI-906 or Placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene.
Principal Investigator: Laura Chow. Role: Co-Investigator

A Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (VENTIRX).
Principal Investigator: Laura Chow. Role: Co-Investigator

A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (PANHER PFIZER A7471009).
Role: Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer (HOPE 303).
Role: Principal Investigator

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin or Carboplatin/Paclitaxel on Subjects with Treatment-Naïve Stage IIIB/IV Non-small Cell Lung Cancer (BMS TWELVE).
Principal Investigator: Laura Chow. Role: Co-Investigator.

A Randomized, Phase II, Multicenter, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment for Patients with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (GO SQUAM).
Role: Principal Investigator

A Randomized, Phase II, Multicenter, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients with Stage IIIB (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC) (GO NON-SQUAM).
Role: Principal Investigator

Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers.
Principal Investigator: Keith Eaton. Role: Co-Investigator

Phase II study of weekly ABRAXANE (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR (EGFR ABRAXANE).
Principal Investigator: Christina Baik. Role: Co-Investigator

NCCN Investigator Initiated Solid Tumor Grant (NCCN SOLID TUMOR).
Principal Investigator: Laura Chow. Role: Co-Investigator

An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer (NSCLC).
Principal Investigator: Laura Chow. Role: Co-Investigator

A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (THOR 7797).
Role: Principal Investigator

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin or Carboplatin/Paclitaxel on Subjects with Treatment-naïve Stage IIIB/IV Non-Small Cell Lung Cancer.
Principal Investigator: Laura Chow. Role: Co-Investigator

A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) (HSP 90).
Role: Principal Investigator

A Phase II, Multicenter, Single-Arm Study of Oral LDK378 in Crizotinib Naïve Adult Patients with ALK-Activated Non-Small Cell Lung Cancer (LDK ONE).
Role: Principal Investigator

A Phase II, Multicenter, Single-Arm Study of Oral LDK378 in Adult Patients with ALK-Activated Non-Small Cell Lung Cancer Previously Treated with Chemotherapy and Crizotinib (LDK THREE).
Role: Principal Investigator

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations.
Principal Investigator: Christina Baik. Role: Co-Investigator

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Principal Investigator: Laura Chow. Role: Co-Investigator

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients with Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity.
Principal Investigator: Christina Baik. Role: Co-Investigator.

Training

Dr. Martins received his MD from Federal University of Rio de Janeiro, Brazil. He completed his Internal Medicine Residency at Gundersen Clinic, La Crosse, WI . He was a Post-Doctoral Fellow in Hematology/Oncology at Massachusetts General/Harvard Medical School, Boston, MA.

Selected Publications

Fidias P, Supko JG, Martins R, et al. A phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced non-small Cell Lung Cancer. Clin Cancer Res 7: 3942-9, 2001.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.

Martins RG. Treatment of Locally-Advanced Non Small Cell Lung Cancer with Combination of Chemotherapy and Radiation. Seminars in Respiratory & Critical Care Medicine 26(3): 273-77, 2005.

Martins RG, Dienstmann R, de Biasi P, Dantas K, Santos V, Toscano E, Roriz W. Zamboni M, Sousa A, Smaill IA, Moreira D, Ferreira CG, Zukin M. Phase II trial of neoadjuvant chemotherapy using alternating doublet in non-small-cell lung cancer. Clinical Lung Cancer 2007 Jan;8(4):257-63.

Bauman JE, Eaton KD, and Martins RG. Antagonism of Platelet-Derived Growth Factor Receptor in Non-Small Cell Lung Cancer: Rationale and Investigations.  Clin Cancer Res. 2007 Aug 1;13(15):4632s-6s.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.

Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr. Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):294-314.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20;26(15):2442-9.

Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care May;14(5):297-306, 2008.

Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. Ann Thorac Surg. 2008;86:1632-9.

Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):556-61.

Eaton KD, Martins RG. Maintenance chemotherapy in non-small cell lung cancer.  J Natl Compr Canc Netw. 2010 Jul;8(7):815-21. Review.

Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.  Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer.  J Clin Oncol. 2010 Nov 20;28(33):4953-60.

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell F, Dziadziuszko R, Richardson K, Richardson F, Wolf JL, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn Jr PA, Camidge DR.  Erlotinib Alone Superior in Patients with Activating EGFR Mutations:  A Randomized Phase II Biomarker Selected Study Comparing Erlotinib to Erlotinib Intercalated with Chemotherapy in 1st Line Therapy for Advanced Non-Small Cell Lung Cancer.  J Clin Oncol. 2011 Sep 10;29(26):3567-3573.

A Shaw, DN Hayes, R Martins.  The Importance of Histology and Molecular Testing (EGFR and EML4-ALK) in the Initial Evaluation of Advanced Non-small Cell Lung Cancer.  2011 ASCO Educational Book 292-298.

Martins RG, D’Amico  TA, Loo BW, Pinder-Schenck M, Borgaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. Accepted for publication in JNCCN, May 2012.

Last updated: February 2013

Top